首页 > 最新文献

Recent patents on biotechnology最新文献

英文 中文
Decarbonizing the Transport of Microalgae-based Products - The Role of E-mobility. 微藻产品运输的去碳化--电动交通的作用。
Q3 Biochemistry, Genetics and Molecular Biology Pub Date : 2024-04-15 DOI: 10.2174/0118722083305025240409071630
R. R. Dias, Mariany C. Deprá, Victor Cesar Rodrigues Carvalho, Cristiano Ragagnin de Menezes, L. Q. Zepka, E. Jacob‐Lopes
BACKGROUNDThe decarbonization of road transport is a precondition for achieving carbon neutrality. Battery-electric vehicle technology can make this a reality. In this bias, the objective of the article is to shed light on the ongoing debate about the potentially important role of the adoption of electric vehicles in the transport of microalgae- based products to help them advance to a cleaner life cycle.METHODSFive routes, including unimodal and multimodal conditions, were defined to assess the carbon emissions of the transport system and, more specifically, of road transport. The headquarters of market-leading microalgae manufacturers were selected as the origin of the routes and, as the destination, regions that sustain them.RESULTSThe results reveal the supremacy of road transport of microalgae-based products using electric vehicles powered by nuclear, hydroelectric, and wind, followed by biomass and photovoltaic energy. They also show that the positive impact of wind, water, and photovoltaic energy on the climate, added to the lower battery charging costs and the greater opportunity to generate revenue from the sale of carbon credits, make their tradeoffs.CONCLUSIONThe exquisite results of this study convey key messages to decision-makers and stakeholders about the role of electromobility in building a zero-carbon delivery route.
背景 公路运输的去碳化是实现碳中和的先决条件。电池电动汽车技术可以实现这一目标。在这种情况下,文章的目的是阐明目前关于采用电动汽车在微藻产品运输中的潜在重要作用的讨论,以帮助微藻产品进入更清洁的生命周期。方法确定了五条路线,包括单式和多式联运条件,以评估运输系统的碳排放量,更具体地说,是公路运输的碳排放量。结果结果表明,使用核能、水能和风能驱动的电动汽车进行微藻产品的公路运输具有优势,其次是生物质能和光伏能。研究结果还表明,风能、水能和光伏能对气候产生积极影响,而且电池充电成本较低,有更多机会通过出售碳信用额度获得收益,因此可以权衡利弊。结论本研究的精美结果向决策者和利益相关者传达了有关电动交通在建设零碳运输路线中的作用的关键信息。
{"title":"Decarbonizing the Transport of Microalgae-based Products - The Role of E-mobility.","authors":"R. R. Dias, Mariany C. Deprá, Victor Cesar Rodrigues Carvalho, Cristiano Ragagnin de Menezes, L. Q. Zepka, E. Jacob‐Lopes","doi":"10.2174/0118722083305025240409071630","DOIUrl":"https://doi.org/10.2174/0118722083305025240409071630","url":null,"abstract":"BACKGROUND\u0000The decarbonization of road transport is a precondition for achieving carbon neutrality. Battery-electric vehicle technology can make this a reality. In this bias, the objective of the article is to shed light on the ongoing debate about the potentially important role of the adoption of electric vehicles in the transport of microalgae- based products to help them advance to a cleaner life cycle.\u0000\u0000\u0000METHODS\u0000Five routes, including unimodal and multimodal conditions, were defined to assess the carbon emissions of the transport system and, more specifically, of road transport. The headquarters of market-leading microalgae manufacturers were selected as the origin of the routes and, as the destination, regions that sustain them.\u0000\u0000\u0000RESULTS\u0000The results reveal the supremacy of road transport of microalgae-based products using electric vehicles powered by nuclear, hydroelectric, and wind, followed by biomass and photovoltaic energy. They also show that the positive impact of wind, water, and photovoltaic energy on the climate, added to the lower battery charging costs and the greater opportunity to generate revenue from the sale of carbon credits, make their tradeoffs.\u0000\u0000\u0000CONCLUSION\u0000The exquisite results of this study convey key messages to decision-makers and stakeholders about the role of electromobility in building a zero-carbon delivery route.","PeriodicalId":21064,"journal":{"name":"Recent patents on biotechnology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140700922","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Nutritional Health Connection of Algae and its Pharmaceutical Value as Anticancer and Antioxidant Constituents of Drugs 海藻的营养保健作用及其作为抗癌和抗氧化药物成分的药用价值
Q3 Biochemistry, Genetics and Molecular Biology Pub Date : 2024-03-27 DOI: 10.2174/0118722083287672240321081428
S. Mirza, Sidra Akbar, Muhammad Umer Ijaz, Mohammad Hossein Morowvat, Ayesha Ishaque, Kalsoom Fatima
The marine environment is one of the major biomass producers of algae andseaweed; it is rich in functional ingredients or active metabolites with valuable nutritionalhealth effects. Algal Metabolites derived from the cultivation of both microalgae andmacroalgae may positively impact human health, offering physiological, pharmaceuticaland nutritional benefits. Microalgae have been widely used as novel sources of bioactivesubstances. Bioactive polymers extracted from algae, such as algal fucans, Galatians, alginatesphenolics, carotenoids, vitamin B12, and peptides possess antioxidant, anticoagulant,antimicrobial, antiviral, anti-inflammatory, anti-allergy, anticancer, and hypocholesterolemicproperties. It emphasizes that using marine-derived compounds with bioactiveproperties as functional food ingredients may help promote human health and preventchronic diseases. Utilizing bioactive compounds has demonstrated notable advantages interms of effectiveness more than conventional treatments and therapies currently in use.Despite the availability of numerous microalgae-derived products catering to humanhealth and nutrition in the market, there remains a lack of social acceptance and awarenessregarding the health benefits of microalgae. Hence, this review aims to offer a comprehensiveaccount of the current knowledge on anticancers, antioxidants, commerciallyavailable edible algal products and therapeutics isolated from algae.
海洋环境是藻类和海藻的主要生物质生产地之一;它富含具有宝贵营养保健作用的功能成分或活性代谢物。从微藻类和大型藻类培养中提取的藻类代谢物可对人类健康产生积极影响,提供生理、药物和营养方面的益处。微藻已被广泛用作生物活性物质的新来源。从海藻中提取的生物活性聚合物,如海藻岩藻素、加拉太藻素、海藻酚、类胡萝卜素、维生素 B12 和肽,具有抗氧化、抗凝血、抗菌、抗病毒、抗炎、抗过敏、抗癌和降胆固醇等特性。报告强调,使用具有生物活性特性的海洋衍生化合物作为功能性食品配料,有助于促进人类健康和预防慢性疾病。与目前使用的传统治疗方法和疗法相比,利用生物活性化合物已显示出显著的有效性优势。尽管市场上有许多微藻衍生产品可满足人类健康和营养的需求,但社会对微藻的健康益处仍然缺乏认可和认识。因此,本综述旨在全面介绍当前有关抗癌、抗氧化剂、商业化食用藻类产品以及从藻类中分离出的治疗药物的知识。
{"title":"Nutritional Health Connection of Algae and its Pharmaceutical Value as Anticancer and Antioxidant Constituents of Drugs","authors":"S. Mirza, Sidra Akbar, Muhammad Umer Ijaz, Mohammad Hossein Morowvat, Ayesha Ishaque, Kalsoom Fatima","doi":"10.2174/0118722083287672240321081428","DOIUrl":"https://doi.org/10.2174/0118722083287672240321081428","url":null,"abstract":"\u0000\u0000The marine environment is one of the major biomass producers of algae and\u0000seaweed; it is rich in functional ingredients or active metabolites with valuable nutritional\u0000health effects. Algal Metabolites derived from the cultivation of both microalgae and\u0000macroalgae may positively impact human health, offering physiological, pharmaceutical\u0000and nutritional benefits. Microalgae have been widely used as novel sources of bioactive\u0000substances. Bioactive polymers extracted from algae, such as algal fucans, Galatians, alginates\u0000phenolics, carotenoids, vitamin B12, and peptides possess antioxidant, anticoagulant,\u0000antimicrobial, antiviral, anti-inflammatory, anti-allergy, anticancer, and hypocholesterolemic\u0000properties. It emphasizes that using marine-derived compounds with bioactive\u0000properties as functional food ingredients may help promote human health and prevent\u0000chronic diseases. Utilizing bioactive compounds has demonstrated notable advantages in\u0000terms of effectiveness more than conventional treatments and therapies currently in use.\u0000Despite the availability of numerous microalgae-derived products catering to human\u0000health and nutrition in the market, there remains a lack of social acceptance and awareness\u0000regarding the health benefits of microalgae. Hence, this review aims to offer a comprehensive\u0000account of the current knowledge on anticancers, antioxidants, commercially\u0000available edible algal products and therapeutics isolated from algae.\u0000","PeriodicalId":21064,"journal":{"name":"Recent patents on biotechnology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-03-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140375069","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Role of Artificial Intelligence in Drug Discovery to Revolutionizethe Pharmaceutical Industry: Resources, Methods and Applications 人工智能在药物发现中的作用将彻底改变制药业:资源、方法和应用
Q3 Biochemistry, Genetics and Molecular Biology Pub Date : 2024-03-21 DOI: 10.2174/0118722083297406240313090140
P. Singh, Kapil Sachan, Vishal Khandelwal, Sumita Singh, Smita Singh
Traditional drug discovery methods such as wet-lab testing, validations, andsynthetic techniques are time-consuming and expensive. Artificial Intelligence (AI) approacheshave progressed to the point where they can have a significant impact on thedrug discovery process. Using massive volumes of open data, artificial intelligencemethods are revolutionizing the pharmaceutical industry. In the last few decades, manyAI-based models have been developed and implemented in many areas of the drug developmentprocess. These models have been used as a supplement to conventional researchto uncover superior pharmaceuticals expeditiously. Drug research and developmentto repurposing and productivity benefits in the pharmaceutical business throughclinical trials. AI is studied in this article for its numerous potential uses. We have discussedhow AI can be put to use in the pharmaceutical sector, specifically for predicting adrug's toxicity, bioactivity, and physicochemical characteristics, among other things. Inthis review article, we have discussed its application to a variety of problems, includingde novo drug discovery, target structure prediction, interaction prediction, and binding affinityprediction. AI for predicting drug interactions and nanomedicines were also considered.
传统的药物发现方法,如湿实验室测试、验证和合成技术,既耗时又昂贵。人工智能(AI)方法已经发展到可以对药物发现过程产生重大影响的地步。利用海量开放数据,人工智能方法正在彻底改变制药行业。在过去的几十年里,许多基于人工智能的模型已经被开发出来,并在药物开发过程的许多领域得到了应用。这些模型被用作传统研究的补充,以迅速发现优质药品。从药物研发到再利用,再到通过临床试验为制药企业带来生产效益。本文研究了人工智能的众多潜在用途。我们讨论了如何将人工智能用于制药领域,特别是用于预测药物的毒性、生物活性和理化特性等。在这篇综述文章中,我们讨论了人工智能在各种问题上的应用,包括新药发现、靶点结构预测、相互作用预测和结合亲和力预测。此外,还考虑了用于预测药物相互作用和纳米药物的人工智能。
{"title":"Role of Artificial Intelligence in Drug Discovery to Revolutionize\u0000the Pharmaceutical Industry: Resources, Methods and Applications","authors":"P. Singh, Kapil Sachan, Vishal Khandelwal, Sumita Singh, Smita Singh","doi":"10.2174/0118722083297406240313090140","DOIUrl":"https://doi.org/10.2174/0118722083297406240313090140","url":null,"abstract":"\u0000\u0000Traditional drug discovery methods such as wet-lab testing, validations, and\u0000synthetic techniques are time-consuming and expensive. Artificial Intelligence (AI) approaches\u0000have progressed to the point where they can have a significant impact on the\u0000drug discovery process. Using massive volumes of open data, artificial intelligence\u0000methods are revolutionizing the pharmaceutical industry. In the last few decades, many\u0000AI-based models have been developed and implemented in many areas of the drug development\u0000process. These models have been used as a supplement to conventional research\u0000to uncover superior pharmaceuticals expeditiously. Drug research and development\u0000to repurposing and productivity benefits in the pharmaceutical business through\u0000clinical trials. AI is studied in this article for its numerous potential uses. We have discussed\u0000how AI can be put to use in the pharmaceutical sector, specifically for predicting a\u0000drug's toxicity, bioactivity, and physicochemical characteristics, among other things. In\u0000this review article, we have discussed its application to a variety of problems, including\u0000de novo drug discovery, target structure prediction, interaction prediction, and binding affinity\u0000prediction. AI for predicting drug interactions and nanomedicines were also considered.\u0000","PeriodicalId":21064,"journal":{"name":"Recent patents on biotechnology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-03-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140388110","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Development of a Novel Peptide with RGD Tumor Homing Motif: Evaluation of its Anticancer Potential in Hepatocellular Carcinoma and Colon Cancer Cells 开发具有 RGD 肿瘤归巢基团的新型多肽:评估其在肝细胞癌和结肠癌细胞中的抗癌潜力
Q3 Biochemistry, Genetics and Molecular Biology Pub Date : 2024-03-20 DOI: 10.2174/0118722083300452240315035722
Reda Abdallah Mohamed, Ohoud M. Marie, Dahlia I. Badran, O. Hammam, Hend Okasha
Peptide-based therapy has emerged as a promising avenue fortreating various disorders, and recent research has highlighted the potential of anti-cancerpeptides (ACPs) in cancer treatment. In this context, this study aimed to design a novelpeptide incorporating a tumor-homing peptide (RGD) and C-amidation to enhance its anticanceractivity, particularly against liver (HepG2) and colon (HCT-116) cancer cell lines.The primary objective was to design a peptide with improved anticancerproperties by leveraging the tumor-homing capabilities of RGD and enhancing its activitythrough C-amidation. The study sought to evaluate the cytotoxicity of the designedpeptide against red blood cells (RBCs) and normal Vero cells. Furthermore, the anticancerefficacy of the peptide was assessed in hepatocellular carcinoma (HepG2) and coloncancer (HCT-116) cell lines. The specific objectives included examining the apoptoticinduction and morphological changes in treated cells compared to untreated cells.The peptide was designed using the ACPred-FL bioinformatics tool, and itscytotoxicity was assessed through hemolysis assays against RBCs and normal Vero cells.Anticancer activity was evaluated against HepG2 and HCT-116 cell lines. The analysisof apoptotic induction involved measuring the relative gene expression of oncogenicmarker BCL2 and apoptotic markers (BAX, BID, CAS-8). Additionally, Cytopathologicalexamination and Western Blot analysis were employed to study morphologicalchanges and confirm the quantification of relevant markers.The designed peptide, consisting of twelve amino acids with a molecular massof 1230.6233 Da and an isoelectric point of 9.81, exhibited low erythrocyte lysis andminimal toxicity to normal cells. The IC50 values demonstrated significant anticanceractivity against both HepG2 (36.49±2.6 μg/mL) and HCT-116 (11.03±2.5 μg/mL) celllines. Treated cells exhibited a significant decrease in the oncogenic marker BCL2 and anupregulation of apoptotic markers (BAX, BID, CAS-8). Western Blot analysis confirmedthese findings, and Cytopathological examination revealed scattered apoptotic and degenerativechanges.The designed peptide displayed remarkable anticancer activity againsthepatocellular carcinoma and colon cancer cell lines, effectively modulating apoptoticand oncogenic markers. These findings highlight the potential of the peptide as a therapeuticagent for cancer treatment, emphasizing its clinical significance in combating liverand colon cancers. Nonetheless, further research and development are warranted to explorethe translational potential of this peptide in clinical settings.
基于肽的疗法已成为治疗各种疾病的一种前景广阔的途径,最近的研究强调了抗癌肽(ACPs)在癌症治疗中的潜力。在此背景下,本研究旨在设计一种新型多肽,该多肽结合了肿瘤定位肽(RGD)和C-酰胺化,以增强其抗癌活性,尤其是针对肝癌(HepG2)和结肠癌(HCT-116)细胞系的抗癌活性。研究试图评估所设计的多肽对红细胞(RBC)和正常 Vero 细胞的细胞毒性。此外,还评估了该肽在肝癌(HepG2)和结肠癌(HCT-116)细胞系中的抗癌功效。该多肽是利用 ACPred-FL 生物信息学工具设计的,其毒性通过针对红细胞和正常 Vero 细胞的溶血试验进行评估。凋亡诱导分析包括测量致癌标记物 BCL2 和凋亡标记物(BAX、BID、CAS-8)的相对基因表达。所设计的肽由 12 个氨基酸组成,分子质量为 1230.6233 Da,等电点为 9.81,红细胞裂解率低,对正常细胞的毒性极小。其 IC50 值显示了对 HepG2(36.49±2.6 μg/mL)和 HCT-116 (11.03±2.5 μg/mL)细胞系的显著抗癌活性。经处理的细胞表现出致癌标记物 BCL2 的显著下降和凋亡标记物(BAX、BID、CAS-8)的上调。所设计的多肽对肝细胞癌和结肠癌细胞系具有显著的抗癌活性,能有效调节细胞凋亡和致癌标志物。这些发现凸显了多肽作为癌症治疗剂的潜力,强调了它在抗击肝癌和结肠癌方面的临床意义。尽管如此,仍需进一步研究和开发,以挖掘该肽在临床中的转化潜力。
{"title":"Development of a Novel Peptide with RGD Tumor Homing Motif: Evaluation of its Anticancer Potential in Hepatocellular Carcinoma and Colon Cancer Cells","authors":"Reda Abdallah Mohamed, Ohoud M. Marie, Dahlia I. Badran, O. Hammam, Hend Okasha","doi":"10.2174/0118722083300452240315035722","DOIUrl":"https://doi.org/10.2174/0118722083300452240315035722","url":null,"abstract":"\u0000\u0000Peptide-based therapy has emerged as a promising avenue for\u0000treating various disorders, and recent research has highlighted the potential of anti-cancer\u0000peptides (ACPs) in cancer treatment. In this context, this study aimed to design a novel\u0000peptide incorporating a tumor-homing peptide (RGD) and C-amidation to enhance its anticancer\u0000activity, particularly against liver (HepG2) and colon (HCT-116) cancer cell lines.\u0000\u0000\u0000\u0000The primary objective was to design a peptide with improved anticancer\u0000properties by leveraging the tumor-homing capabilities of RGD and enhancing its activity\u0000through C-amidation. The study sought to evaluate the cytotoxicity of the designed\u0000peptide against red blood cells (RBCs) and normal Vero cells. Furthermore, the anticancer\u0000efficacy of the peptide was assessed in hepatocellular carcinoma (HepG2) and colon\u0000cancer (HCT-116) cell lines. The specific objectives included examining the apoptotic\u0000induction and morphological changes in treated cells compared to untreated cells.\u0000\u0000\u0000\u0000The peptide was designed using the ACPred-FL bioinformatics tool, and its\u0000cytotoxicity was assessed through hemolysis assays against RBCs and normal Vero cells.\u0000Anticancer activity was evaluated against HepG2 and HCT-116 cell lines. The analysis\u0000of apoptotic induction involved measuring the relative gene expression of oncogenic\u0000marker BCL2 and apoptotic markers (BAX, BID, CAS-8). Additionally, Cytopathological\u0000examination and Western Blot analysis were employed to study morphological\u0000changes and confirm the quantification of relevant markers.\u0000\u0000\u0000\u0000The designed peptide, consisting of twelve amino acids with a molecular mass\u0000of 1230.6233 Da and an isoelectric point of 9.81, exhibited low erythrocyte lysis and\u0000minimal toxicity to normal cells. The IC50 values demonstrated significant anticancer\u0000activity against both HepG2 (36.49±2.6 μg/mL) and HCT-116 (11.03±2.5 μg/mL) cell\u0000lines. Treated cells exhibited a significant decrease in the oncogenic marker BCL2 and an\u0000upregulation of apoptotic markers (BAX, BID, CAS-8). Western Blot analysis confirmed\u0000these findings, and Cytopathological examination revealed scattered apoptotic and degenerative\u0000changes.\u0000\u0000\u0000\u0000The designed peptide displayed remarkable anticancer activity against\u0000hepatocellular carcinoma and colon cancer cell lines, effectively modulating apoptotic\u0000and oncogenic markers. These findings highlight the potential of the peptide as a therapeutic\u0000agent for cancer treatment, emphasizing its clinical significance in combating liver\u0000and colon cancers. Nonetheless, further research and development are warranted to explore\u0000the translational potential of this peptide in clinical settings.\u0000","PeriodicalId":21064,"journal":{"name":"Recent patents on biotechnology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-03-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140389125","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Patents Selections 专利选择
Q3 Biochemistry, Genetics and Molecular Biology Pub Date : 2024-03-01 DOI: 10.2174/187220831801231013004218
{"title":"Patents Selections","authors":"","doi":"10.2174/187220831801231013004218","DOIUrl":"https://doi.org/10.2174/187220831801231013004218","url":null,"abstract":"","PeriodicalId":21064,"journal":{"name":"Recent patents on biotechnology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140085654","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Meet the Editorial Board Member 认识编辑委员会成员
Q3 Biochemistry, Genetics and Molecular Biology Pub Date : 2024-03-01 DOI: 10.2174/187220831801231012235532
Younes Ghasemi
{"title":"Meet the Editorial Board Member","authors":"Younes Ghasemi","doi":"10.2174/187220831801231012235532","DOIUrl":"https://doi.org/10.2174/187220831801231012235532","url":null,"abstract":"","PeriodicalId":21064,"journal":{"name":"Recent patents on biotechnology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140092338","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Construction of Camelus dromedaries Immune Single Domain Antibodies Library for Development of Schistosoma mansoni Specific Nanobodies Using Phage Display Strategy 利用噬菌体展示策略构建用于开发曼氏血吸虫特异性纳米抗体的骆驼免疫单域抗体库
Q3 Biochemistry, Genetics and Molecular Biology Pub Date : 2024-01-29 DOI: 10.2174/0118722083275669231227063413
Hadeer Adel El-Kalamawy, Mohamed Awwad, Tarek Diab, Hend Okasha, Amal M. Abdel-Kareim, M. Marawan, Salma A. Shoulah, E. El-Dabaa
Schistosoma mansoni poses a considerable global public healthchallenge. In Egypt, approximately 60% of the inhabitants in the Northern and Easternareas of the Nile Delta are affected by this parasite, whereas the Southern region experiencesa significantly lower infection rate of 6%.Schistosoma (S.) mansoni infect 60% of the population in the Northern and Eastern parts of the Nile Delta and only 6% in the Southern part. Therefore, seeking for cost effective, sensitive and specific diagnostic tool for rapid detection of S. mansoni is necessary. Variable domains of camelid heavy-chain antibodies (VHHs) which are known as nanobodies (Nb) are approximately 15 kDa in size with high affinity to their antigens. Phage display technology was used in construction of Nbs library based on the camelid VHH framework for selection of S. mansoni specific NbsConstruction of an immune phage display Nbs library based on the VHH frameworkfor selecting S. mansoni-specific Nbs for seeking cost-effective, sensitive, and specificdiagnostic tools for rapidly detecting Schistosoma mansoni.Camel was immunized using soluble adult worm antigens (SAWP) for the productionof Variable domains of heavy chains of camelid heavy-chain only antibodies(VHHs), which are known as nanobodies (Nb). The PBMCs repertoires VHH sequenceslibrary have been constructed with a high percentage of insertion and right orientation usingpADL-23c phagmid and M13 phage followed by three rounds of bio-panning againstSAWP using phage display technique. Evaluations using polyclonal phage ELISA andother techniques have been carried out to reveal the successful enrichment of anti-SAWPNbs (VHH) clones. Evaluation of the diagnostic potentiality of these Nbs was carried outusing ELISA on human serum samples confirmed for S. mansoni infection. Receiver Operatorof Characteristics (ROC) curve analysis was used for discrimination between S.mansoni infection and both negative controls and the Fasciola hepatica group.Using monoclonal ELISA, Nbs of 22 clones out of 24 selected clones showedbinding affinity to SAWP. The cutoff values of the produced anti-S. mansoni Nbs was >0.19, leading to 80% sensitivity, 95% specificity, and 90% accuracy. Sequence analysis ofthree of these Nbs with high binding affinities showed diversity in their targets, consideringtheir CDR3 aa sequences.Using monoclonal ELISA, Nbs of 22 clones out of 24 selected clones showed binding affinity to SAWP. Sequence analysis of three of these Nbs with high binding affinities showed diversity in their targets considering their CDR3 aa sequences.This study successfully produced high diversity, anti-S.mansoni VHHs enrichedphage library and the generated nanobodies have high diagnostic potential for S.mansoni infection in human patients.We had successfully constructed high diversity VHH immune library against S. mansoni SAWP which can be efficiently used to develop anti-S. mansoni Nbs for diagnosis.
曼氏血吸虫对全球公共卫生构成了巨大挑战。在埃及,尼罗河三角洲北部和东部地区约有 60% 的居民受到这种寄生虫的影响,而南部地区的感染率要低得多,仅为 6%。因此,有必要寻找成本效益高、灵敏且特异的诊断工具来快速检测曼氏血吸虫。驼科动物重链抗体(VHHs)的可变结构域被称为纳米抗体(Nb),大小约为 15 kDa,对其抗原具有高亲和力。噬菌体展示技术被用于构建基于驼科动物 VHH 框架的 Nbs 库,以筛选曼森氏杆菌特异性 Nbs。使用可溶性成虫抗原(SAWP)对骆驼进行免疫,以生产驼科动物重链唯一抗体(VHHs)重链的可变域,这种抗体被称为纳米抗体(Nb)。利用pADL-23c噬菌体和M13噬菌体构建了具有高插入率和正确方向的PBMCs Reppertoires VHH序列库,然后利用噬菌体展示技术针对SAWP进行了三轮生物筛选。使用多克隆噬菌体酶联免疫吸附试验(ELISA)和其他技术进行了评估,结果显示成功地富集了抗SAWPNbs(VHH)克隆。对这些 Nbs 的诊断潜力的评估是在确认感染曼森氏杆菌的人类血清样本上使用 ELISA 进行的。利用单克隆酶联免疫吸附法,在筛选出的 24 个克隆中,有 22 个克隆的 Nbs 显示出与 SAWP 的结合亲和力。通过单克隆酶联免疫吸附试验(ELISA),24 个克隆中有 22 个克隆的 Nbs 与 SAWP 有亲和力,所产生的抗 S. mansoni Nbs 的临界值大于 0.19,灵敏度为 80%,特异度为 95%,准确度为 90%。通过单克隆酶联免疫吸附试验(ELISA),在筛选出的24个克隆中,有22个克隆的Nbs显示出与SAWP的结合亲和力。这项研究成功地建立了高分辨率的抗曼氏沙门氏菌VHHs富集噬菌体文库,所产生的纳米抗体对人类患者的曼氏沙门氏菌感染具有很高的诊断潜力。
{"title":"Construction of Camelus dromedaries Immune Single Domain Antibodies Library for Development of Schistosoma mansoni Specific Nanobodies Using Phage Display Strategy","authors":"Hadeer Adel El-Kalamawy, Mohamed Awwad, Tarek Diab, Hend Okasha, Amal M. Abdel-Kareim, M. Marawan, Salma A. Shoulah, E. El-Dabaa","doi":"10.2174/0118722083275669231227063413","DOIUrl":"https://doi.org/10.2174/0118722083275669231227063413","url":null,"abstract":"\u0000\u0000Schistosoma mansoni poses a considerable global public health\u0000challenge. In Egypt, approximately 60% of the inhabitants in the Northern and Eastern\u0000areas of the Nile Delta are affected by this parasite, whereas the Southern region experiences\u0000a significantly lower infection rate of 6%.\u0000\u0000\u0000\u0000Schistosoma (S.) mansoni infect 60% of the population in the Northern and Eastern parts of the Nile Delta and only 6% in the Southern part. Therefore, seeking for cost effective, sensitive and specific diagnostic tool for rapid detection of S. mansoni is necessary. Variable domains of camelid heavy-chain antibodies (VHHs) which are known as nanobodies (Nb) are approximately 15 kDa in size with high affinity to their antigens. Phage display technology was used in construction of Nbs library based on the camelid VHH framework for selection of S. mansoni specific Nbs\u0000\u0000\u0000\u0000Construction of an immune phage display Nbs library based on the VHH framework\u0000for selecting S. mansoni-specific Nbs for seeking cost-effective, sensitive, and specific\u0000diagnostic tools for rapidly detecting Schistosoma mansoni.\u0000\u0000\u0000\u0000Camel was immunized using soluble adult worm antigens (SAWP) for the production\u0000of Variable domains of heavy chains of camelid heavy-chain only antibodies\u0000(VHHs), which are known as nanobodies (Nb). The PBMCs repertoires VHH sequences\u0000library have been constructed with a high percentage of insertion and right orientation using\u0000pADL-23c phagmid and M13 phage followed by three rounds of bio-panning against\u0000SAWP using phage display technique. Evaluations using polyclonal phage ELISA and\u0000other techniques have been carried out to reveal the successful enrichment of anti-SAWP\u0000Nbs (VHH) clones. Evaluation of the diagnostic potentiality of these Nbs was carried out\u0000using ELISA on human serum samples confirmed for S. mansoni infection. Receiver Operator\u0000of Characteristics (ROC) curve analysis was used for discrimination between S.\u0000mansoni infection and both negative controls and the Fasciola hepatica group.\u0000\u0000\u0000\u0000Using monoclonal ELISA, Nbs of 22 clones out of 24 selected clones showed\u0000binding affinity to SAWP. The cutoff values of the produced anti-S. mansoni Nbs was >\u00000.19, leading to 80% sensitivity, 95% specificity, and 90% accuracy. Sequence analysis of\u0000three of these Nbs with high binding affinities showed diversity in their targets, considering\u0000their CDR3 aa sequences.\u0000\u0000\u0000\u0000Using monoclonal ELISA, Nbs of 22 clones out of 24 selected clones showed binding affinity to SAWP. Sequence analysis of three of these Nbs with high binding affinities showed diversity in their targets considering their CDR3 aa sequences.\u0000\u0000\u0000\u0000This study successfully produced high diversity, anti-S.mansoni VHHs enriched\u0000phage library and the generated nanobodies have high diagnostic potential for S.\u0000mansoni infection in human patients.\u0000\u0000\u0000\u0000We had successfully constructed high diversity VHH immune library against S. mansoni SAWP which can be efficiently used to develop anti-S. mansoni Nbs for diagnosis.\u0000","PeriodicalId":21064,"journal":{"name":"Recent patents on biotechnology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-01-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140485930","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Edible Vaccines: A Patent-Driven Exploration of Immunization Technologies. 食用疫苗:专利驱动的免疫技术探索。
Q3 Biochemistry, Genetics and Molecular Biology Pub Date : 2024-01-25 DOI: 10.2174/0118722083275041231219060829
Sahil Kashyap, Shikha Kamboj, Rohit Kamboj, Kumar Guarve, Sweta Kamboj

Vaccines are biological preparations that improve immunity to particular diseases. Particularly for poor developing nations, edible vaccines show significant potential as a financially advantageous, simple to administer, straightforward to store, fail-safe, and socially and culturally acceptable vaccine delivery system. A vaccine incorporates the gene-encoding bacterial or viral disease-causing agent in plants without losing its immunogenic property. Potatoes, tomatoes, rice, soybeans, and bananas are the primary plants for edible vaccines. It activates the systemic and mucosal immunity responses against a foreign disease-causing organism. It offers exciting possibilities to reduce diseases like hepatitis B, rabies, HIV/AIDS (human immunodeficiency virus infection and acquired immune deficiency syndrome), etc. These vaccines provide many benefits, like being convenient to administer, efficiently storing, and readily acceptable drug delivery systems for patients of different age groups. So, an edible vaccine may be the most convenient vaccine to improve immunity. However, there are a lot of technical and regulatory challenges to overcome in the way of edible vaccine technology. Though all seem surmountable, various technical obstacles and regulatory and non-scientific challenges need to be overcome. Moreover, edible vaccine patents represent a cutting-edge area of biotechnology, where the integration of genetic material into edible substances holds great promise for revolutionizing vaccination methods. These patents aim to harness the potential of plants and other edibles to stimulate immune responses, offering a potential alternative to traditional injectable vaccines. This review states the technologies, host plants, current status, recent patents, the future of this new preventive modality, and different regulatory issues concerning edible vaccines.

疫苗是一种生物制剂,可提高对特定疾病的免疫力。特别是对于贫穷的发展中国家来说,可食用疫苗作为一种经济上有利、管理简单、易于储存、安全可靠以及社会和文化上可接受的疫苗输送系统,显示出巨大的潜力。疫苗将编码细菌或病毒致病因子的基因植入植物中,而不会失去其免疫原性。马铃薯、西红柿、大米、大豆和香蕉是可食用疫苗的主要植物。它能激活全身和粘膜免疫反应,抵御外来致病生物。它为减少乙型肝炎、狂犬病、艾滋病毒/艾滋病(人类免疫缺陷病毒感染和获得性免疫缺陷综合征)等疾病提供了令人兴奋的可能性。这些疫苗有很多好处,比如方便接种、有效储存,以及适合不同年龄段患者的给药系统。因此,可食用疫苗可能是提高免疫力最方便的疫苗。然而,在可食用疫苗技术的发展道路上,还有许多技术和监管方面的挑战需要克服。尽管所有这些似乎都可以克服,但各种技术障碍以及监管和非科学挑战仍需克服。此外,可食用疫苗专利代表了生物技术的一个前沿领域,将遗传物质融入可食用物质有望彻底改变疫苗接种方法。这些专利旨在利用植物和其他可食用物质的潜力来刺激免疫反应,为传统注射疫苗提供潜在的替代方案。本综述介绍了可食用疫苗的技术、宿主植物、现状、最新专利、这一新型预防方式的未来,以及与可食用疫苗有关的各种监管问题。
{"title":"Edible Vaccines: A Patent-Driven Exploration of Immunization Technologies.","authors":"Sahil Kashyap, Shikha Kamboj, Rohit Kamboj, Kumar Guarve, Sweta Kamboj","doi":"10.2174/0118722083275041231219060829","DOIUrl":"https://doi.org/10.2174/0118722083275041231219060829","url":null,"abstract":"<p><p>Vaccines are biological preparations that improve immunity to particular diseases. Particularly for poor developing nations, edible vaccines show significant potential as a financially advantageous, simple to administer, straightforward to store, fail-safe, and socially and culturally acceptable vaccine delivery system. A vaccine incorporates the gene-encoding bacterial or viral disease-causing agent in plants without losing its immunogenic property. Potatoes, tomatoes, rice, soybeans, and bananas are the primary plants for edible vaccines. It activates the systemic and mucosal immunity responses against a foreign disease-causing organism. It offers exciting possibilities to reduce diseases like hepatitis B, rabies, HIV/AIDS (human immunodeficiency virus infection and acquired immune deficiency syndrome), etc. These vaccines provide many benefits, like being convenient to administer, efficiently storing, and readily acceptable drug delivery systems for patients of different age groups. So, an edible vaccine may be the most convenient vaccine to improve immunity. However, there are a lot of technical and regulatory challenges to overcome in the way of edible vaccine technology. Though all seem surmountable, various technical obstacles and regulatory and non-scientific challenges need to be overcome. Moreover, edible vaccine patents represent a cutting-edge area of biotechnology, where the integration of genetic material into edible substances holds great promise for revolutionizing vaccination methods. These patents aim to harness the potential of plants and other edibles to stimulate immune responses, offering a potential alternative to traditional injectable vaccines. This review states the technologies, host plants, current status, recent patents, the future of this new preventive modality, and different regulatory issues concerning edible vaccines.</p>","PeriodicalId":21064,"journal":{"name":"Recent patents on biotechnology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-01-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139567388","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Medicinal Plants in the Treatment of Respiratory Diseases and their Future Aspects. 药用植物在呼吸系统疾病治疗中的作用及其未来前景。
Q3 Biochemistry, Genetics and Molecular Biology Pub Date : 2024-01-24 DOI: 10.2174/0118722083278561231212072408
Aliya Firdaus, Mohd Hadi Yunus, Syed Khalida Izhar, Uzma Afaq

The utilization of medicinal plants in the treatment of respiratory diseases has a rich history dating back centuries. This study delves into the diverse range of plant species known for their therapeutic properties, with a specific focus on their applications in respiratory health. Medicinal plants have played a crucial role as a source of ingredients for medications and the synthesis of drugs. Globally, over 35,000 plant species are employed for medicinal purposes, particularly in emerging countries where traditional medicine, predominantly plant-based pharmaceuticals, serves as a primary healthcare resource. This review highlights the significance of medicinal plants, such as aloe, ginger, turmeric, tulsi, and neem, in treating a wide array of common respiratory ailments. These plants contain bioactive compounds, including tannins, alkaloids, sugars, terpenoids, steroids, and flavonoids, which have diverse therapeutic applications. Some medicinal plants, notably Echinacea purpurea and Zingiber officinale, exhibit potential for adjuvant symptomatic therapy in respiratory conditions, such as chronic obstructive pulmonary disease (COPD), bronchitis, asthma, the common cold, cough, and whooping cough. The leaves of medicinal plants like Acacia torta, Ocimum sanctum, Mentha haplocalyx, Lactuca virosa, Convolvulus pluricaulis, and Acalypha indica are commonly used to address pneumonia, bronchitis, asthma, colds, and cough. This review aims to shed light on specific medicinal plants with therapeutic value, providing valuable insights for researchers in the field of herbal medicine. These plants hold the potential to serve as novel therapeutic agents in the treatment of respiratory diseases.

利用药用植物治疗呼吸系统疾病的历史可以追溯到几个世纪以前。本研究深入探讨了各种具有治疗特性的植物物种,特别关注它们在呼吸系统健康方面的应用。作为药物成分和药物合成的来源,药用植物发挥着至关重要的作用。全球有超过 35,000 种植物被用于药用目的,特别是在新兴国家,以植物药为主的传统医学成为主要的医疗资源。本综述强调了芦荟、生姜、姜黄、涂尔西和印楝等药用植物在治疗各种常见呼吸道疾病方面的重要作用。这些植物含有生物活性化合物,包括鞣质、生物碱、糖类、萜类、类固醇和类黄酮,具有多种治疗用途。一些药用植物,特别是紫锥菊和细辛,具有辅助治疗呼吸系统疾病的潜力,如慢性阻塞性肺病(COPD)、支气管炎、哮喘、普通感冒、咳嗽和百日咳。药用植物如金合欢(Acacia torta)、圣女果(Ocimum sanctum)、薄荷(Mentha haplocalyx)、紫苏乳(Lactuca virosa)、旋花(Convolvulus pluricaulis)和苘麻(Acalypha indica)的叶子常用于治疗肺炎、支气管炎、哮喘、感冒和咳嗽。本综述旨在阐明具有治疗价值的特定药用植物,为草药领域的研究人员提供有价值的见解。这些植物有望成为治疗呼吸系统疾病的新型治疗剂。
{"title":"Medicinal Plants in the Treatment of Respiratory Diseases and their Future Aspects.","authors":"Aliya Firdaus, Mohd Hadi Yunus, Syed Khalida Izhar, Uzma Afaq","doi":"10.2174/0118722083278561231212072408","DOIUrl":"https://doi.org/10.2174/0118722083278561231212072408","url":null,"abstract":"<p><p>The utilization of medicinal plants in the treatment of respiratory diseases has a rich history dating back centuries. This study delves into the diverse range of plant species known for their therapeutic properties, with a specific focus on their applications in respiratory health. Medicinal plants have played a crucial role as a source of ingredients for medications and the synthesis of drugs. Globally, over 35,000 plant species are employed for medicinal purposes, particularly in emerging countries where traditional medicine, predominantly plant-based pharmaceuticals, serves as a primary healthcare resource. This review highlights the significance of medicinal plants, such as aloe, ginger, turmeric, tulsi, and neem, in treating a wide array of common respiratory ailments. These plants contain bioactive compounds, including tannins, alkaloids, sugars, terpenoids, steroids, and flavonoids, which have diverse therapeutic applications. Some medicinal plants, notably Echinacea purpurea and Zingiber officinale, exhibit potential for adjuvant symptomatic therapy in respiratory conditions, such as chronic obstructive pulmonary disease (COPD), bronchitis, asthma, the common cold, cough, and whooping cough. The leaves of medicinal plants like Acacia torta, Ocimum sanctum, Mentha haplocalyx, Lactuca virosa, Convolvulus pluricaulis, and Acalypha indica are commonly used to address pneumonia, bronchitis, asthma, colds, and cough. This review aims to shed light on specific medicinal plants with therapeutic value, providing valuable insights for researchers in the field of herbal medicine. These plants hold the potential to serve as novel therapeutic agents in the treatment of respiratory diseases.</p>","PeriodicalId":21064,"journal":{"name":"Recent patents on biotechnology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-01-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139562963","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Designing a Secretory form of RTX-A as an Anticancer Toxin: AnIn Silico Approach 设计一种分泌型 RTX-A 作为抗癌毒素:硅学方法
Q3 Biochemistry, Genetics and Molecular Biology Pub Date : 2024-01-08 DOI: 10.2174/0118722083267796231210060150
Mortaza Taheri‐Anganeh, Navid Nezafat, S. Gharibi, S. H. Khatami, Farzaneh Vahedi, Zahra Shabaninejad, Marzieh Asadi, A. Savardashtaki, A. Movahedpour, Hassan Ghasemi
Cancer is a leading cause of death and a significant public healthissue worldwide. Standard treatment methods such as chemotherapy, radiotherapy, andsurgery are only sometimes effective. Therefore, new therapeutic approaches are neededfor cancer treatment. Sea anemone actinoporins are pore-forming toxins (PFTs) withmembranolytic activities. RTX-A is a type of PFT that interacts with membrane phospholipids, resulting in pore formation. The synthesis of recombinant proteins in a secretoryform has several advantages, including protein solubility and easy purification. In thisstudy, we aimed to discover suitable signal peptides for producing RTX-A in Bacillussubtilis in a secretory form.Signal peptides were selected from the Signal Peptide Web Server. The probability and secretion pathways of the selected signal peptides were evaluated using theSignalP server. ProtParam and Protein-sol were used to predict the physico-chemicalproperties and solubility. AlgPred was used to predict the allergenicity of RTX-A linkedto suitable signal peptides. Non-allergenic, stable, and soluble signal peptides fused toproteins were chosen, and their secondary and tertiary structures were predicted usingGOR IV and I-TASSER, respectively. The PROCHECK server performed the validationof 3D structures.According to bioinformatics analysis, the fusion forms of OSMY_ECOLI andMALE_ECOLI linked to RTX-A were identified as suitable signal peptides. The finalproteins with signal peptides were stable, soluble, and non-allergenic for the human body.Moreover, they had appropriate secondary and tertiary structures.The signal above peptides appears ideal for rationalizing secretory and soluble RTX-A. Therefore, the signal peptides found in this study should be further investigated through experimental research.
癌症是导致死亡的主要原因之一,也是全球重要的公共卫生问题。标准的治疗方法,如化疗、放疗和手术,只是有时有效。因此,癌症治疗需要新的治疗方法。海葵肌动蛋白是一种具有膜溶解活性的孔形成毒素(PFTs)。RTX-A 是一种与膜磷脂相互作用导致孔隙形成的 PFT。以分泌物形式合成重组蛋白具有多种优势,包括蛋白可溶性和易于纯化。在这项研究中,我们的目标是发现适合于在芽孢杆菌中以分泌形式生产 RTX-A 的信号肽。从信号肽网络服务器上选择信号肽,使用信号肽服务器(SignalP)评估所选信号肽的可能性和分泌途径。ProtParam 和 Protein-sol 用于预测信号肽的物理化学性质和溶解度。AlgPred 用于预测 RTX-A 与合适信号肽连接后的过敏性。选择了与蛋白质融合的非过敏性、稳定和可溶性信号肽,并分别使用 GOR IV 和 I-TASSER 预测了它们的二级和三级结构。根据生物信息学分析,OSMY_ECOLI和MALE_ECOLI与RTX-A的融合形式被确定为合适的信号肽。带有信号肽的最终蛋白质稳定、可溶、对人体无过敏性,而且具有适当的二级和三级结构。因此,本研究发现的信号肽应通过实验研究进行进一步研究。
{"title":"Designing a Secretory form of RTX-A as an Anticancer Toxin: An\u0000In Silico Approach","authors":"Mortaza Taheri‐Anganeh, Navid Nezafat, S. Gharibi, S. H. Khatami, Farzaneh Vahedi, Zahra Shabaninejad, Marzieh Asadi, A. Savardashtaki, A. Movahedpour, Hassan Ghasemi","doi":"10.2174/0118722083267796231210060150","DOIUrl":"https://doi.org/10.2174/0118722083267796231210060150","url":null,"abstract":"\u0000\u0000Cancer is a leading cause of death and a significant public health\u0000issue worldwide. Standard treatment methods such as chemotherapy, radiotherapy, and\u0000surgery are only sometimes effective. Therefore, new therapeutic approaches are needed\u0000for cancer treatment. Sea anemone actinoporins are pore-forming toxins (PFTs) with\u0000membranolytic activities. RTX-A is a type of PFT that interacts with membrane phospholipids, resulting in pore formation. The synthesis of recombinant proteins in a secretory\u0000form has several advantages, including protein solubility and easy purification. In this\u0000study, we aimed to discover suitable signal peptides for producing RTX-A in Bacillus\u0000subtilis in a secretory form.\u0000\u0000\u0000\u0000Signal peptides were selected from the Signal Peptide Web Server. The probability and secretion pathways of the selected signal peptides were evaluated using the\u0000SignalP server. ProtParam and Protein-sol were used to predict the physico-chemical\u0000properties and solubility. AlgPred was used to predict the allergenicity of RTX-A linked\u0000to suitable signal peptides. Non-allergenic, stable, and soluble signal peptides fused to\u0000proteins were chosen, and their secondary and tertiary structures were predicted using\u0000GOR IV and I-TASSER, respectively. The PROCHECK server performed the validation\u0000of 3D structures.\u0000\u0000\u0000\u0000According to bioinformatics analysis, the fusion forms of OSMY_ECOLI and\u0000MALE_ECOLI linked to RTX-A were identified as suitable signal peptides. The final\u0000proteins with signal peptides were stable, soluble, and non-allergenic for the human body.\u0000Moreover, they had appropriate secondary and tertiary structures.\u0000\u0000\u0000\u0000The signal above peptides appears ideal for rationalizing secretory and soluble RTX-A. Therefore, the signal peptides found in this study should be further investigated through experimental research.\u0000","PeriodicalId":21064,"journal":{"name":"Recent patents on biotechnology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-01-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139446514","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Recent patents on biotechnology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1